| Dr Joseph W Nelson, DO | |
|
2265 Fillmore Ave, Ogden, UT 84401-2136 | |
| (480) 444-9940 | |
| Not Available |
| Full Name | Dr Joseph W Nelson |
|---|---|
| Gender | Male |
| Speciality | Family Medicine |
| Location | 2265 Fillmore Ave, Ogden, Utah |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1316122427 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 7133384-1204 (Utah) | Primary |
| Entity Name | Canyon Medical Home Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1588150981 PECOS PAC ID: 0749532265 Enrollment ID: O20181011001384 |
News Archive
Boston Scientific Corporation today announced the settlement of three patent disputes with Johnson & Johnson (J&J). The disputes date back to 2003 and cover Boston Scientific's Jang patent and J&J's Palmaz and Gray patents, all of which involve intellectual property in the cardiovascular arena. Boston Scientific will make a $1.725 billion payment to J&J in connection with the settlement.
Stateline reports that new federal rules that limit state options for cutting Medicaid have moved health care providers and patient advocates nearer to testing the legality of the cuts in court. In the meantime, Medicaid cuts and restructuring remain in play in dwindling state budgets as Oregon, Ohio and Kansas look for ways to save money in the state-federal health care program for the poor.
Santarus, Inc., a specialty biopharmaceutical company, today announced that new data from open-label studies evaluating the efficacy and safety of the investigational drug RHUCIN for the treatment of acute attacks of angioedema in patients with Hereditary Angioedema were presented at the 7th C1 Inhibitor Deficiency Workshop on May 20 - 22, 2011 in Budapest, Hungary.
Accelerated Cure Project for Multiple Sclerosis (ACP) announced today that Genentech, Inc., a member of the Roche Group, has become a Founding Sponsor for the Optimizing Treatment - Understanding Progression (OPT-UP) clinical study in multiple sclerosis (MS).
Glycosylated proteins are often overexpressed in tumor cells and thus could serve as tumor markers, especially those with the interesting molecule sialic acid as their sugar moiety.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Joseph W Nelson, DO 2265 Fillmore Ave, Ogden, UT 84401-2136 Ph: (480) 444-9940 | Dr Joseph W Nelson, DO 2265 Fillmore Ave, Ogden, UT 84401-2136 Ph: (480) 444-9940 |
News Archive
Boston Scientific Corporation today announced the settlement of three patent disputes with Johnson & Johnson (J&J). The disputes date back to 2003 and cover Boston Scientific's Jang patent and J&J's Palmaz and Gray patents, all of which involve intellectual property in the cardiovascular arena. Boston Scientific will make a $1.725 billion payment to J&J in connection with the settlement.
Stateline reports that new federal rules that limit state options for cutting Medicaid have moved health care providers and patient advocates nearer to testing the legality of the cuts in court. In the meantime, Medicaid cuts and restructuring remain in play in dwindling state budgets as Oregon, Ohio and Kansas look for ways to save money in the state-federal health care program for the poor.
Santarus, Inc., a specialty biopharmaceutical company, today announced that new data from open-label studies evaluating the efficacy and safety of the investigational drug RHUCIN for the treatment of acute attacks of angioedema in patients with Hereditary Angioedema were presented at the 7th C1 Inhibitor Deficiency Workshop on May 20 - 22, 2011 in Budapest, Hungary.
Accelerated Cure Project for Multiple Sclerosis (ACP) announced today that Genentech, Inc., a member of the Roche Group, has become a Founding Sponsor for the Optimizing Treatment - Understanding Progression (OPT-UP) clinical study in multiple sclerosis (MS).
Glycosylated proteins are often overexpressed in tumor cells and thus could serve as tumor markers, especially those with the interesting molecule sialic acid as their sugar moiety.
› Verified 2 days ago
Scott Allen Andelin, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 4403 Harrison Blvd, Ste A-700, Ogden, UT 84403 Phone: 801-387-5300 | |
John M Hemmersmeier, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 5740 Crestwood Dr, Ogden, UT 84405 Phone: 801-479-7771 Fax: 801-479-7795 | |
Kristine M Oates, M.D. Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 4403 Harrison Blvd, Ste. A700, Ogden, UT 84403 Phone: 801-387-5300 Fax: 801-387-5335 | |
Benjamin Zachary Larsen, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 4403 Harrison Blvd Ste 700a, Ogden, UT 84403 Phone: 801-387-5300 Fax: 801-387-5333 | |
Robert L Adams, MD Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 1355 Hinkley Dr, Ogden, UT 84401 Phone: 801-387-6050 | |
Mary Ellen Mason, DO Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 4650 Harrison Blvd, Ogden, UT 84403 Phone: 801-475-3010 Fax: 801-475-3001 | |
Brett Wayne Martindale, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 4700 Harrison Blvd, Ogden, UT 84403 Phone: 801-475-3300 Fax: 801-475-3301 |